公开(公告)号：WO2015025228A3

公开(公告)日：2015-02-26

申请号：PCT/IB2014/002560

申请日：2014-08-21

申请人： RESVERLOGIX CORP.

发明人： LEBIODA, Kenneth, Eugene ,  JOHANSSON, Jan, Ove ,  GORDON, F., Allan ,  CHIACCHIA, Fabrizio, Simone ,  HALLIDAY, Christopher, Ross, Armstrong ,  KULIKOWSKI, Ewelina, B.

IPC分类号： A61K31/517 ,  A61K31/47 ,  A61K31/505 ,  A61K31/519 ,  A61P9/10

摘要： The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of a compound of Formula I or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin.

公开(公告)号：WO2021090061A1

公开(公告)日：2021-05-14

申请号：PCT/IB2020/000912

申请日：2020-11-04

申请人： RESVERLOGIX CORP.

发明人： LEBIODA, Kenneth, Eugene ,  HALLIDAY, Christopher Ross Armstrong ,  KHAN, Aziz Naeem

IPC分类号： A61K31/517 ,  A61P9/00 ,  C07D239/91

摘要： Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE), by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

公开(公告)号：WO2021140418A1

公开(公告)日：2021-07-15

申请号：PCT/IB2021/000006

申请日：2021-01-07

申请人： RESVERLOGIX CORP.

发明人： LEBIODA, Kenneth, Eugene ,  HALLIDAY, Christopher, Ross Armstrong ,  KHAN, Aziz, Naeem

IPC分类号： A61K31/517 ,  A61K31/40 ,  A61K31/403 ,  A61K31/427 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/522 ,  A61K38/095 ,  A61P9/00 ,  A61P9/10 ,  C07D207/16 ,  C07D209/52 ,  C07D239/91 ,  C07D401/04 ,  C07D417/14 ,  C07D473/06 ,  C07D487/04

摘要： Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE) by administering to a subject in need thereof, a combination of a dipeptidyl peptidase 4 (DPP-4) inhibitor and a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula (I) are as defined herein.

公开(公告)号：WO2015025226A2

公开(公告)日：2015-02-26

申请号：PCT/IB2014/002546

申请日：2014-08-21

申请人： RESVERLOGIX CORP.

发明人： LEBIODA, Kenneth, Eugene ,  JOHANSSON, Jan, Ove ,  GORDON, F., Allan ,  CHIACCHIA, Fabrizio, Simone ,  HALLIDAY, Christopher, Ross, Armstrong ,  KULIKOWSKI, Ewelina, B.

IPC分类号： A61K31/517

CPC分类号： A61K31/517 ,  A61K31/505 ,  A61K2300/00

摘要： The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of RVX-208 or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. The invention further provides compositions comprising a therapeutically effective amount of RVX-208 or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明包括通过共同施用治疗有效量的RVX-208或其药学上可接受的盐和罗苏伐他汀或其药学上可接受的盐来治疗和/或预防心血管，胆固醇和脂质相关疾病，包括动脉粥样硬化的方法。 本发明还提供包含治疗有效量的RVX-208或其药学上可接受的盐和治疗有效量的瑞舒伐他汀或其药学上可接受的盐的组合物。